Do analysts rate WEED or MJN?

Canopy Growth presently has a consensus price target of C$1.88, indicating a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Canopy Growth is more favorable than Cronos Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, WEED or MJN?

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$293.63M 1.94 -C$1.05B -C$0.67 N/A Cronos Group N/A N/A N/A N/A N/A

Which has higher valuation and earnings, CRON or WEED?

Cronos Group has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$179.09M 9.90 -C$32.78M C$0.19 25.32 Canopy Growth C$293.63M 1.94 -C$1.05B -C$0.67 N/A

Do analysts prefer CARA or WEED?

Canopy Growth has a consensus price target of C$1.88, indicating a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts plainly believe Canopy Growth is more favorable than Cara Operations. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation and earnings, CARA or WEED?

Cara Operations has higher earnings, but lower revenue than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Canopy Growth C$293.63M 1.94 -C$1.05B -C$0.67 N/A

Do analysts rate THCX or WEED?

Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation & earnings, THCX or WEED?

Hydropothecary has higher earnings, but lower revenue than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hydropothecary N/A N/A N/A N/A N/A Canopy Growth C$293.63M 1.94 -C$1.05B -C$0.67 N/A

Canopy Growth (WEED) Competitors

C$1.35 -0.03 (-2.17%)

As of 09/23/2026 04:00 PM Eastern

Compare

WEED vs. MJN, CRON, CARA, GUD, and THCX

Should you buy Canopy Growth stock or one of its competitors? Canopy Growth's main competitors and comparable companies include Cronos Group (MJN), Cronos Group (CRON), Cara Operations (CARA), Knight Therapeutics (GUD), and Hydropothecary (THCX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Canopy Growth compare to Cronos Group?

Canopy Growth (TSE:WEED) and Cronos Group (CVE:MJN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

In the previous week, Canopy Growth's average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Canopy Growth	Neutral
Cronos Group	Neutral

Cronos Group has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Cronos Group's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Cronos Group	N/A	N/A	N/A

Cronos Group has lower revenue, but higher earnings than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.94	-C$1.05B	-C$0.67	N/A
Cronos Group	N/A	N/A	N/A	N/A	N/A

Canopy Growth presently has a consensus price target of C$1.88, indicating a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.3% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Canopy Growth beats Cronos Group on 6 of the 9 factors compared between the two stocks.

How does Canopy Growth compare to Cronos Group?

Cronos Group (TSE:CRON) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

4.3% of Cronos Group shares are held by institutional investors. Comparatively, 4.3% of Canopy Growth shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Comparatively, 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cronos Group has a net margin of 38.95% compared to Canopy Growth's net margin of -73.95%. Cronos Group's return on equity of 6.46% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	38.95%	6.46%	-3.73%
Canopy Growth	-73.95%	-29.85%	-3.83%

Cronos Group currently has a consensus target price of C$4.92, suggesting a potential upside of 2.22%. Canopy Growth has a consensus target price of C$1.88, suggesting a potential upside of 38.89%. Given Canopy Growth's higher possible upside, analysts plainly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cronos Group has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$179.09M	9.90	-C$32.78M	C$0.19	25.32
Canopy Growth	C$293.63M	1.94	-C$1.05B	-C$0.67	N/A

Cronos Group has a beta of 1.29991, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.634762, indicating that its stock price is 63% more volatile than the broader market.

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score.

Company	Overall Sentiment
Cronos Group	Neutral
Canopy Growth	Neutral

Summary

Cronos Group beats Canopy Growth on 11 of the 14 factors compared between the two stocks.

How does Canopy Growth compare to Cara Operations?

Cara Operations (TSE:CARA) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Cara Operations has higher earnings, but lower revenue than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Canopy Growth	C$293.63M	1.94	-C$1.05B	-C$0.67	N/A

Canopy Growth has a consensus price target of C$1.88, indicating a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts plainly believe Canopy Growth is more favorable than Cara Operations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cara Operations has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Cara Operations' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Canopy Growth	-73.95%	-29.85%	-3.83%

4.3% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cara Operations' average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score.

Company	Overall Sentiment
Cara Operations	Neutral
Canopy Growth	Neutral

Summary

Canopy Growth beats Cara Operations on 6 of the 9 factors compared between the two stocks.

How does Canopy Growth compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Knight Therapeutics has a beta of -0.290935, suggesting that its stock price is 129% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.634762, suggesting that its stock price is 63% more volatile than the broader market.

Knight Therapeutics presently has a consensus target price of C$9.50, indicating a potential downside of 5.85%. Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 38.89%. Given Canopy Growth's higher possible upside, analysts clearly believe Canopy Growth is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

22.7% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.3% of Canopy Growth shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Comparatively, 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Knight Therapeutics had 1 more articles in the media than Canopy Growth. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Canopy Growth. Knight Therapeutics' average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Canopy Growth	Neutral

Knight Therapeutics has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$547.31M	1.81	-C$30.73M	C$0.15	67.27
Canopy Growth	C$293.63M	1.94	-C$1.05B	-C$0.67	N/A

Knight Therapeutics has a net margin of 2.72% compared to Canopy Growth's net margin of -73.95%. Knight Therapeutics' return on equity of 1.91% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	2.72%	1.91%	0.51%
Canopy Growth	-73.95%	-29.85%	-3.83%

Summary

Knight Therapeutics beats Canopy Growth on 11 of the 15 factors compared between the two stocks.

How does Canopy Growth compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

4.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Hydropothecary's average media sentiment score of 0.00 equaled Canopy Growth'saverage media sentiment score.

Company	Overall Sentiment
Hydropothecary	Neutral
Canopy Growth	Neutral

Hydropothecary has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Hydropothecary's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hydropothecary	N/A	N/A	N/A
Canopy Growth	-73.95%	-29.85%	-3.83%

Hydropothecary has higher earnings, but lower revenue than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hydropothecary	N/A	N/A	N/A	N/A	N/A
Canopy Growth	C$293.63M	1.94	-C$1.05B	-C$0.67	N/A

Summary

Canopy Growth beats Hydropothecary on 6 of the 9 factors compared between the two stocks.

Get Canopy Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WEED vs. The Competition

Export

Metric	Canopy Growth	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$571.10M	C$12.60B	C$7.31B	C$12.84B
Dividend Yield	4.80%	2.63%	2.52%	6.27%
P/E Ratio	-2.01	792.28	274.08	40.36
Price / Sales	1.94	862.22	638.21	9.35
Price / Cash	1.63	88.64	77.80	82.29
Price / Book	0.83	10.59	10.47	4.69
Net Income	-C$1.05B	C$2.81B	C$3.49B	C$299.09M
7 Day Performance	3.05%	-0.11%	-0.67%	0.01%
1 Month Performance	-7.53%	-1.34%	-3.17%	-2.14%
1 Year Performance	-31.82%	2.86%	15.14%	20.17%

Canopy Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WEED Canopy Growth	1.787 of 5 stars	C$1.35 -2.2%	C$1.88 +38.9%	-26.2%	C$571.10M	C$293.63M	N/A	2,700
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	N/A	7,600
CRON Cronos Group	1.2957 of 5 stars	C$4.46 -1.3%	C$4.92 +10.2%	+32.1%	C$1.64B	C$179.09M	23.47	610
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
GUD Knight Therapeutics	0.3685 of 5 stars	C$9.96 -0.6%	C$9.50 -4.6%	+67.1%	C$978.39M	C$547.31M	66.40	830	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:WEED) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Canopy Growth (WEED) Competitors

WEED vs. MJN, CRON, CARA, GUD, and THCX

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to Cara Operations?

Summary

How does Canopy Growth compare to Knight Therapeutics?

Summary

How does Canopy Growth compare to Hydropothecary?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Canopy Growth (WEED) Competitors

WEED vs. MJN, CRON, CARA, GUD, and THCX

How does Canopy Growth compare to Cronos Group?

Does the media prefer WEED or MJN?

Is WEED or MJN more profitable?

Which has higher earnings and valuation, WEED or MJN?

Do analysts rate WEED or MJN?

Do institutionals and insiders have more ownership in WEED or MJN?

Summary

How does Canopy Growth compare to Cronos Group?

Do insiders & institutionals hold more shares of CRON or WEED?

Is CRON or WEED more profitable?

Do analysts prefer CRON or WEED?

Which has higher valuation and earnings, CRON or WEED?

Which has more volatility & risk, CRON or WEED?

Does the media prefer CRON or WEED?

Summary

How does Canopy Growth compare to Cara Operations?

Which has stronger valuation and earnings, CARA or WEED?

Do analysts prefer CARA or WEED?

Is CARA or WEED more profitable?

Do insiders and institutionals have more ownership in CARA or WEED?

Does the media prefer CARA or WEED?

Summary

How does Canopy Growth compare to Knight Therapeutics?

Which has more volatility and risk, GUD or WEED?

Do analysts recommend GUD or WEED?

Do insiders & institutionals have more ownership in GUD or WEED?

Does the media refer more to GUD or WEED?

Which has stronger earnings and valuation, GUD or WEED?

Is GUD or WEED more profitable?

Summary

How does Canopy Growth compare to Hydropothecary?

Do analysts rate THCX or WEED?

Do insiders & institutionals have more ownership in THCX or WEED?

Does the media refer more to THCX or WEED?

Is THCX or WEED more profitable?

Which has better valuation & earnings, THCX or WEED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools